TransMedics Shares Surge After Strong Q1 Earnings Report

Shares of TransMedics Group (NASDAQ: TMDX) recently jumped following an unexpectedly strong first-quarter earnings report. After experiencing downward revenue guidance and unwelcome scrutiny from short-sellers last year, the stock’s recent performance indicates a positive turnaround for the company.

From the end of 2024 through the close on Monday, May 12, TransMedics’ stock soared approximately 81%. Investors are now eager to determine whether this upward trend will continue.

To evaluate the growth potential of TransMedics, it is essential to examine the factors that contributed to its recent surge alongside the challenges that lie ahead.

Image source: Getty Images.

Understanding TransMedics’ Stock Volatility

TransMedics began 2025 on a shaky note due to a slowdown in revenue growth. Despite a remarkable 83% annual revenue increase in 2024, a critical short report in January led to investor skepticism regarding the company’s capacity for sustained growth. Compounding this, the management team’s forecast for revenue growth only reached 20% to 25% for the current year.

Specializing in an organ care system (OCS), TransMedics’ device enhances the preservation of donated hearts, lungs, and livers by pumping warm blood through them. This represents a significant improvement over traditional ice-cooling methods. While the OCS is currently the only FDA-approved device for transporting multiple organs, other warm perfusion devices, such as the OrganOx Metra, have emerged as competitors.

The OrganOx Metra, approved by the FDA in 2021, targets liver preservation and presents a potential competitive threat, as liver transplants account for 76% of TransMedics’ revenue. Recently, OrganOx raised $160 million to bolster its market position in organ transportation. However, recent first-quarter results suggest that OrganOx has yet to pose a substantial challenge, evidenced by a 62% year-over-year increase in liver revenue for TransMedics, exceeding previous quarterly figures by 22%.

Encouraged by these results and the competitive landscape, TransMedics raised its revenue guidance for the year to between $565 million and $585 million, indicating an anticipated gain of 30% at the range’s midpoint.

Future Outlook

Between 2021 and 2023, overall heart, lung, and liver transplant volumes in the U.S. rose by 20%, totaling 17,792 transplants, with TransMedics driving much of this increase. Notably, transplant figures for organs not involving TransMedics saw only a 2% gain during that timeframe.

With over 103,000 Americans currently on the national transplant waiting list, the bulk—approximately 89,792—are awaiting kidney transplants. Since kidneys are typically donated more readily and don’t require specialized transportation, this market is less advantageous for TransMedics.

Although expanding into the kidney market is unlikely to provide a significant boost, capturing greater market share in hearts, lungs, and livers could enable TransMedics to sustain annual sales growth above 20% for several years. The company’s share of these organ markets has expanded from 7% in 2022 to 21% in 2024.

Investment Considerations

Currently, TransMedics stock trades at 8.5 times its trailing-12-month sales, a valuation that may seem high for a medical device company. However, this valuation appears justified if the company can sustain approximately 20% annual growth over the next decade.

The strong first-quarter liver revenue suggests OrganOx is not yet a fierce competitor. Still, given that the privately-held company is now well-funded, it may be wise for investors to wait another quarter to confirm that TransMedics can maintain its growth trajectory in the face of potential competition.

Final Thoughts on Investing in TransMedics Group

Before making an investment in TransMedics Group, consider this:

The Motley Fool Stock Advisor analyst team has identified what they believe are the 10 best stocks to buy currently, and TransMedics Group is notably not included. The selected stocks are believed to hold significant potential for strong returns in the coming years.

For context, consider when Netflix was recommended on December 17, 2004 — if you invested $1,000 then, you’d have $614,911 today!* Or Nvidia, which was highlighted on April 15, 2005 — a $1,000 investment at that time would now be worth $714,958!*

The Stock Advisor’s average total return is 907 % — significantly outperforming the S&P 500, which stands at 163%.

Cory Renauer has positions in TransMedics Group. The Motley Fool has positions in and recommends TransMedics Group. The Motley Fool has a disclosure policy.

The views expressed here belong to the author and do not necessarily reflect those of Nasdaq, Inc.